Alen J Salerian
The Salerian Center and Doctors for Equal Rights for Physical and Mental Pain, USA
Alen J Salerian is the medical director of Salerian Center and the President of Doctors for Equal Rights for Mental and Physical pain. He is a psycho pharmacologist who currently divides his energy between research and advocacy for people with chronic and mental pain. He has practiced in Washington DC for four decades, taught at George Washington University medical Center, served as the FBI's medical director of Mobile Psychiatric Emergency Response Team and is the medical director of Salerian Center for Neuroscience and Pain. He has published numerous articles in peer-reviewed journals including Lancet, Psychiatric Research, CNS Spectrum, Medical hypotheses, Journal of Psychology and Clinical Psychiatry contributed to Washington Post LA Times. He also appeared on CBS 60 minutes, Panorama (BBC). He has published two books, Viagra for your brain and Honest Moments with Dr. Shrink (cartoons). His forensic study of JFKs assassination JFK images will soon to be released.
Salerian Center for Neuroscience and Pain is a private institution in Washington DC with a dual mission of Hippocratic medicine and science. This presentation reviews endorphins and endorphin agonists in treatment of chronic pain, addiction, depression chronic pain with depression and psychosis with endorphins as the common crucial variable. There is compelling evidence that endorphins and endorphin agonists are of vital importance in the genesis and treatment of chronic pain, addiction, depression, chronic pain with depression and psychosis. This presentation reviews biology of regional brain dysfunction, neurotransmitters, mechanism of action of antidepressant strategies, preclinical data over antidepressant effects of endorphins, clinical data of antidepressant effects of endorphins, common pathways of pain and depression and addresses common challenges associated with therapeutic interventions with endorphin like substances. The engineering of slow-release endorphins agonists have enabled possible effective treatments for diverse neuropsychiatric conditions with relatively low risk of overuse or adverse events. Further double-blind studies will be helpful to validate these findings.